Document is current

Article History

Accepted: 18 April 2025

First Online: 21 May 2025

Declarations

:

: Financial support was provided by AstraZeneca and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, who are codeveloping olaparib.

: Fred Saad has received consultancy and advisory fees from AbbVie, Advanced Accelerator Applications, Astellas Pharma, AstraZeneca/MedImmune, Bayer, Janssen Oncology, Knight Therapeutics, Myovant Sciences, Novartis, Pfizer, and Sanofi; honoraria from AbbVie, Advanced Accelerator Applications, Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Janssen Oncology, Knight Therapeutics, Merck, Myovant Sciences, Novartis, Pfizer, and Sanofi; and institutional research funding from Advanced Accelerator Applications, Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Janssen Oncology, Merck, Novartis, Pfizer, and Sanofi. Andrew J. Armstrong has received consultancy or advisory fees from Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Clovis Oncology, Dendreon, Exelixis, FORMA Therapeutics, GoodRX, Janssen, Merck, Myovant Sciences, Novartis, and Pfizer; travel and accommodation expenses from Astellas; and institutional research funding from Amgen, Astellas Pharma, AstraZeneca, Bayer, BeiGene, Bristol Myers Squibb, Constellation Pharmaceuticals, Dendreon, FORMA Therapeutics, Janssen Oncology, Gilead Sciences, Merck, Novartis, Pfizer, and Roche/Genentech and holds institutional patents, royalties, and other intellectual property for circulating tumor cell novel capture technology. Neal Shore has acted in a consulting or advisory role for AbbVie, Accord, Alessa Therapeutics, Amgen, Antev, Asieris, Astellas, AstraZeneca, Aura Biosciences, Bayer, Bioprotect, Bristol Myers Squibb, Boston Scientific, CGOncology, Clarity, Dendreon, Exact Imaging, Ferring, Fize Medical, Foundation Medicine, Invitae, Janssen, Lantheus, Lilly, Dxhealth, Merck, Minomic, Myriad, Novartis, Pfizer, Photocure, Promaxo, Protara, Sanofi Genzyme, Telix, Tolmar, and Urogen; and in a leadership or fiduciary role for Alessa Photocure and Tuteix. Neal Shore is an editorial board member of Targeted Oncology and as such was not involved in the selection of peer reviewers for the manuscript or any of the subsequent editorial decisions. Daniel J. George has received grants from Calithera, Convergence, and Corvus; grants and personal fees from Astellas, Bristol Myers Squibb, Johnson and Johnson Pharmaceuticals, Merck Sharp & Dohme, Novartis, and Pfizer; personal fees from AstraZeneca, Axess Oncology, Capio Bioscience, Flatiron, Michael J Hennessey Associates, Millennium Medical Publishing, Myovant Sciences Inc, NCI Genitourinary, Nektar Therapeutics, Physician Education Resource, UroGPO, Vizuri Health Sciences, Platform Q, Propella Therapeutics, RevHealth, Seattle Genetics, WebMD, and Xcures; grants, personal fees, and non-financial support from Bayer Healthcare Pharmaceuticals, and Exelixis Inc; personal fees and non-financial support from UroToday; and other support from the American Association for Cancer Research, all outside of the submitted work. Mototsugu Oya has received consultancy or advisory fees from Bayer; honoraria from Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb Japan, Chugai, Janssen, MSD, Novartis, Ono Pharmaceuticals, Pfizer, Sanofi, and Takeda and research funding from Astellas Pharma, Novartis, and Pfizer. Mikio Sugimoto has received honoraria from Astellas, AstraZeneca, Janssen Pharmaceuticals, and Takeda; research funding from Astellas, AstraZeneca, Bristol Myers Squibb, Janssen, MSD, and Pfizer; and travel and accommodation expenses from Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Janssen, and MSD. Rana R. McKay has received institutional grant/research support from AstraZeneca, Bayer, Bristol Myers Squibb, Exelixis, Oncternal, and Tempus; consultancy fees from Arcus, Ambrx, AstraZeneca, Aveo, Bayer, Bristol Myers Squibb, Calithera, Caris, Dendreon, Eisai, Exelixis, Johnson & Johnson, Lilly, Merck, Myovant, NeoMorph, Novartis, Pfizer, Sanofi, SeaGen, Sorrento Therapeutics, Telix, and Tempus. Maha Hussain has received honoraria from AstraZeneca, Bayer, Convergent, Novartis, and Tango; has served on advisory boards and received honoraria for the following invited educational events/lectures/manuscripts: PROST8 Consensus Conference Steering Committee member and session chair (honorarium received from MJH, RTP Lecture, AACR Satellite Symposium Lecture, Academic CME and travel expenses); South Africa Oncology Society lecture (honorarium received from AstraZeneca); Bayer APEX meeting (travel/accommodation, honorarium); 2nd International Genitourinary Cancer Conference Prostate Cancer Educational program (honorarium received from AstraZeneca); PER/NYGU – co-chair/speaker, RTP, Prostate Cancer Diagnostic Medical Education (Virtual) program (honorarium from AstraZeneca). Maha Hussain has also had clinical trials funding contracts with Arvinas, AstraZeneca, Bayer, and Northwestern University. Noel W. Clarke has received institutional consultancy or advisory fees from Astellas Pharma, Bayer, Ferring, Janssen-Cilag, and Sanofi; speaker bureau fees from Astellas Pharma, AstraZeneca, Bayer, Janssen-Cilag, Pfizer, and Sanofi; and travel and accommodation expenses associated with lectures and advisory board meetings from Astellas Pharma, AstraZeneca, Bayer, Ferring, Ipsen, Janssen-Cilag, and Sanofi.

: Not applicable.

: Not applicable.

: Not applicable.

: No new data were generated or analyzed in support of this research.

: Not applicable.

: All authors contributed to the concept and development of this review article, including drafting and critical revision of the manuscript. All authors have approved the submitted version.